Incyte Corp (NAS:INCY)
$ 69.91 0.07 (0.1%) Market Cap: 13.47 Bil Enterprise Value: 11.73 Bil PE Ratio: 499.36 PB Ratio: 4.25 GF Score: 89/100

Incyte Corp at Cowen Healthcare Conference (Virtual) Transcript

Mar 03, 2021 / 07:00PM GMT
Release Date Price: $76.02 (-3.23%)
Marc Alan Frahm
Cowen and Company, LLC, Research Division - Director

Hello. Welcome back to the Cowen Healthcare Conference. Next session is a fireside chat with Incyte. And we're really pleased to have with us CEO, Herve Hoppenot; CMO, Steven Stein; and CFO, Christiana Stamoulis. We will get to Q&A, and we do encourage the audience to participate. (Operator Instructions)

But we'll start off with -- everybody is going to make a few kind of general overview comments, give a status update, and then we will get into specific questions. So Herve?

Herve Hoppenot
Incyte Corporation - Chairman, President & CEO

Yes. Okay. Thank you, Marc. I'll be very quick. I just will show 2 slides. One is about 2020. So you have it in front of you. And what you can see is basically, it was a year where we had 3 products approved by FDA. So it's Monjuvi, it's Pemazyre, it's Tabrecta. So it was an important year of diversification, and obviously, of growth. The top line, the revenue grew at 24% including milestone, 18% without the milestone. So the sort of run rate

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot